SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Alasdair Timothy Llewelyn Rathbone, Surejini Tharmaradinam, Shucui Jiang, Michel P. Rathbone, Dinesh A. Kumbhare, A review of the neuro- and systemic inflammatory responses in post concussion symptoms: Introduction of the “post-inflammatory brain syndrome” PIBS, Brain, Behavior, and Immunity, 2015, 46, 1

    CrossRef

  2. 2
    Susanne Sarkar, Martin Schaefer, Antidepressant Pretreatment for the Prevention of Interferon Alfa–Associated Depression: A Systematic Review and Meta-Analysis, Psychosomatics, 2014, 55, 3, 221

    CrossRef

  3. 3
    Jordan E. Cattie, Scott L. Letendre, Steven Paul Woods, Fatma Barakat, William Perry, Mariana Cherner, Anya Umlauf, Donald Franklin, Robert K. Heaton, Tarek Hassanein, Igor Grant, Persistent neurocognitive decline in a clinic sample of hepatitis C virus-infected persons receiving interferon and ribavirin treatment, Journal of NeuroVirology, 2014, 20, 6, 561

    CrossRef

  4. 4
    Peter A. Shapiro, Richard P. Sloan, Chetram Deochand, Ana M. Franceschi, Christine Delorenzo, J. John Mann, Ramin V. Parsey, Quantifying serotonin transporters by PET with [11C]-DASB before and after interferon-α treatment, Synapse, 2014, 68, 11
  5. 5
    B. H. Mullish, M. S. Kabir, M. R. Thursz, A. Dhar, Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation, Alimentary Pharmacology & Therapeutics, 2014, 40, 8
  6. 6
    Sudhir Mahajan, Ajit Avasthi, Sandeep Grover, Yogesh K. Chawla, Role of baseline depressive symptoms in the development of depressive episode in patients receiving antiviral therapy for Hepatitis C infection, Journal of Psychosomatic Research, 2014, 77, 2, 109

    CrossRef

  7. 7
    Amanda Galvão-de Almeida, Lucas C. Quarantini, Amanda Guindalini Tartaglioni, André C. Lyra, Carmen Lívia Parise, Raymundo Paraná, Irismar R. de Oliveira, Ângela Miranda-Scippa, Camila Guindalini, Serotonin-1A receptor CC genotype is associated with persistent depression related to interferon-alpha in hepatitis C patients, General Hospital Psychiatry, 2014, 36, 3, 255

    CrossRef

  8. 8
    Brian A. Baldo, Side Effects of Cytokines Approved for Therapy, Drug Safety, 2014, 37, 11, 921

    CrossRef

  9. 9
    Benjamin J. R. Stewart, Deborah Turnbull, Antonina A. Mikocka-Walus, Hugh A. J. Harley, Jane M. Andrews, Acceptability of Psychotherapy, Pharmacotherapy, and Self-Directed Therapies in Australians Living with Chronic Hepatitis C, Journal of Clinical Psychology in Medical Settings, 2013, 20, 4, 427

    CrossRef

  10. 10
    Francis E. Lotrich, Barry Sears, Robert K. McNamara, Anger induced by interferon-alpha is moderated by ratio of arachidonic acid to omega-3 fatty acids, Journal of Psychosomatic Research, 2013, 75, 5, 475

    CrossRef

  11. 11
    Waleed Hassan AlMalki, HCV infection: an enigma, recent advances and new paradigms for its treatment, Future Virology, 2013, 8, 4, 381

    CrossRef

  12. 12
    Floor van Heesch, Jolanda Prins, Jan Pieter Konsman, Koen G.C. Westphal, Berend Olivier, Aletta D. Kraneveld, S. Mechiel Korte, Lipopolysaccharide-induced anhedonia is abolished in male serotonin transporter knockout rats: An intracranial self-stimulation study, Brain, Behavior, and Immunity, 2013, 29, 98

    CrossRef

  13. 13
    Shu-Chuan Chang, Chin-Tun Hung, Shu-Fen Li, Horng-Mo Lee, Yueh-Chin Chung, Lee-Wen Pai, Sheng-Shun Yang, Risk of nonpsychotic mental disorders development in antiviral-treated mentally healthy chronic hepatitis C patients: A population-based study, Journal of the Formosan Medical Association, 2013,

    CrossRef

  14. 14
    C L Raison, A H Miller, The evolutionary significance of depression in Pathogen Host Defense (PATHOS-D), Molecular Psychiatry, 2013, 18, 1, 15

    CrossRef

  15. 15
    Eiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, Kazuhiro Takahashi, Hideyuki Nomura, Yuichi Tanabe, Takeaki Satoh, Toshihiro Maruyama, Makoto Nakamuta, Kazuhiro Kotoh, Koichi Azuma, Kazufumi Dohmen, Shinji Shimoda, Jun Hayashi, Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: Results from Kyushu University Liver Disease Study, Journal of Gastroenterology and Hepatology, 2012, 27, 7
  16. 16
    Martin Schaefer, Lucile Capuron, Astrid Friebe, Crisanto Diez-Quevedo, Geert Robaeys, Sergio Neri, Graham R. Foster, Achim Kautz, Daniel Forton, Carmine M. Pariante, Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement, Journal of Hepatology, 2012, 57, 6, 1379

    CrossRef

  17. 17
    Ho-Kyoung Yoon, Yong-Ku Kim, Heon-Jeong Lee, Do-Young Kwon, Leen Kim, Role of cytokines in atypical depression, Nordic Journal of Psychiatry, 2012, 66, 3, 183

    CrossRef

  18. 18
    Sara Baraldi, Nilay Hepgul, Valeria Mondelli, Carmine M. Pariante, Symptomatic Treatment of Interferon-α–Induced Depression in Hepatitis C, Journal of Clinical Psychopharmacology, 2012, 32, 4, 531

    CrossRef

  19. 19
    Vincenza Calvaruso, Marta Mazza, Piero L Almasio, Pegylated-interferon-α2ain clinical practice: how to manage patients suffering from side effects, Expert Opinion on Drug Safety, 2011, 10, 3, 429

    CrossRef

  20. 20
    Brian P. Kurtz, Annah N. Abrams, Psychiatric Aspects of Pediatric Cancer, Pediatric Clinics of North America, 2011, 58, 4, 1003

    CrossRef

  21. 21
    Mary Olson, Ira M. Jacobson, Role of the nurse practitioner in the management of patients with chronic hepatitis C, Journal of the American Academy of Nurse Practitioners, 2011, 23, 8
  22. 22
    Amira Pierucci-Lagha, Jonathan Covault, Herbert L. Bonkovsky, Richard Feinn, Christine Abreu, Richard K. Sterling, Robert J. Fontana, Henry R. Kranzler, A Functional Serotonin Transporter Gene Polymorphism and Depressive Effects Associated With Interferon-α Treatment, Psychosomatics, 2010, 51, 2, 137

    CrossRef

  23. 23
    Mario Furlanut, Giorgio Soardo, Debora Donnini, Leonardo Sechi, Loretta Franceschi, Fluoxetine Disposition in Patients with Chronic Hepatitis C Treated with Interferon-α, Clinical Pharmacokinetics, 2010, 49, 11, 767

    CrossRef

  24. 24
    Brian P. Kurtz, Annah N. Abrams, Psychiatric Aspects of Pediatric Cancer, Child and Adolescent Psychiatric Clinics of North America, 2010, 19, 2, 401

    CrossRef

  25. 25
    Meyler's Side Effects of Drugs in Cancer and Immunology, 2010,

    CrossRef

  26. 26
    Charles L. Raison, Andrey S. Borisov, Matthias Majer, Daniel F. Drake, Giuseppe Pagnoni, Bobbi J. Woolwine, Gerald J. Vogt, Breanne Massung, Andrew H. Miller, Activation of Central Nervous System Inflammatory Pathways by Interferon-Alpha: Relationship to Monoamines and Depression, Biological Psychiatry, 2009, 65, 4, 296

    CrossRef

  27. 27
    Peter Hauser, Benjamin J. Morasco, Alex Linke, Dannell Bjornson, Samantha Ruimy, Annette Matthews, Aly Rifai, David W. Indest, Jennifer M. Loftis, Antiviral Completion Rates and Sustained Viral Response in Hepatitis C Patients With and Without Preexisting Major Depressive Disorder, Psychosomatics, 2009, 50, 5, 500

    CrossRef

  28. 28
    Ana M. Basso, Natalie A. Bratcher, Richard R. Harris, Michael F. Jarvis, Michael W. Decker, Lynne E. Rueter, Behavioral profile of P2X7 receptor knockout mice in animal models of depression and anxiety: Relevance for neuropsychiatric disorders, Behavioural Brain Research, 2009, 198, 1, 83

    CrossRef

  29. 29
    Andrew Aronsohn, Nancy Reau, Long-term Outcomes After Treatment With Interferon and Ribavirin in HCV Patients, Journal of Clinical Gastroenterology, 2009, 43, 7, 661

    CrossRef

  30. 30
    Stephen D. Skaper, Pietro Giusti, P2X7 Receptors as a Transducer in the Co-Occurrence of Neurological/Psychiatric and Cardiovascular Disorders: A Hypothesis, Cardiovascular Psychiatry and Neurology, 2009, 2009, 1

    CrossRef

  31. 31
    Stephen D. Skaper, Patrizia Debetto, Pietro Giusti, P2X7 Receptors in Neurological and Cardiovascular Disorders, Cardiovascular Psychiatry and Neurology, 2009, 2009, 1

    CrossRef

  32. 32
    J.-P. Bronowicki, A. Nani, H. Barraud, Prise en charge des hépatites chroniques virales C ne répondant pas au traitement, Gastroentérologie Clinique et Biologique, 2009, 33, 4, 345

    CrossRef

  33. 33
    Rosa Quelhas, Alice Lopes, Psychiatric Problems in Patients Infected with Hepatitis C Before and During Antiviral Treatment with Interferon-Alpha: A Review, Journal of Psychiatric Practice, 2009, 15, 4, 262

    CrossRef

  34. 34
    Meyler's Side Effects of Psychiatric Drugs, 2009,

    CrossRef

  35. 35
    Stéphane Schmitter, Jean-Philippe Lang, Jean-Pierre Bronowicki, Chantal Henry, Psychiatrie, VIH et hépatite C, 2009,

    CrossRef

  36. 36
    Maurizio Pompili, Paola Tittoto, Roberta Mascianà, Giovanni Gasbarrini, Gian Ludovico Rapaccini, Acute hepatitis associated with use of paroxetine, Internal and Emergency Medicine, 2008, 3, 3, 275

    CrossRef

  37. 37
    C. Wartelle-Bladou, E. Rosenthal, V. Ratziu, V. De Lédinghen, J.-P. Lang, T. Poynard, Adhésion à la bithérapie pégylée au cours de l’hépatite chronique C, Gastroentérologie Clinique et Biologique, 2008, 32, 3, S96

    CrossRef

  38. 38
    Nader Dbouk, Miguel R. Arguedas, Aasim Sheikh, Assessment of the PHQ-9 as a Screening Tool for Depression in Patients with Chronic Hepatitis C, Digestive Diseases and Sciences, 2008, 53, 4, 1100

    CrossRef

  39. 39
    G. Tarantino, V. Basile, P. Conca, M. Ariello, M. N. D. Di Minno, A. Romano, A. Gentile, D. Capone, Could the depression of obese patients suffering from chronic hepatitis C be temporarily improved?, Journal of Viral Hepatitis, 2008, 15, 9
  40. 40
    J.-P. Bronowicki, D. Larrey, A. Tran, C. Perronne, J. Denis, J.-F. Cadranel, C. Trépo, Hépatite C : quelle stratégie en cas d’échec thérapeutique ?, Gastroentérologie Clinique et Biologique, 2008, 32, 3, S109

    CrossRef

  41. 41
    Martin Schaefer, Jochen Winterer, Rahul Sarkar, Ralf Uebelhack, Leonora Franke, Andreas Heinz, Astrid Friebe, Three Cases of Successful Tryptophan Add-On or Monotherapy of Hepatitis C and IFNα-Associated Mood Disorders, Psychosomatics, 2008, 49, 5, 442

    CrossRef

  42. 42
    Benjamin J. Morasco, Muhamad Aly Rifai, Jennifer M. Loftis, David W. Indest, James Kelly Moles, Peter Hauser, A randomized trial of paroxetine to prevent interferon-α-induced depression in patients with hepatitis C, Journal of Affective Disorders, 2007, 103, 1-3, 83

    CrossRef

  43. 43
    Amy A. Dan, Cathy Crone, Thomas N. Wise, Lisa M. Martin, Lolita Ramsey, Scarlett Magee, Robert Sjogren, Janus P. Ong, Zobair M. Younossi, Anger Experiences Among Hepatitis C Patients: Relationship to Depressive Symptoms and Health-Related Quality of Life, Psychosomatics, 2007, 48, 3, 223

    CrossRef

  44. 44
    Yong-Ku Kim, Kyeong-Sae Na, Kyung-Ho Shin, Han-Yong Jung, So-Hyun Choi, Jung-Bum Kim, Cytokine imbalance in the pathophysiology of major depressive disorder, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 5, 1044

    CrossRef

  45. 45
    Dominique Larrey, Patrice Couzigou, Jacques Denis, Hépatite chronique C : gestion des effets indésirables du traitement, Gastroentérologie Clinique et Biologique, 2007, 31, 8-9, 20

    CrossRef

  46. 46
    Brian Keefe, Interferon-induced depression in hepatitis C: An update, Current Psychiatry Reports, 2007, 9, 3, 255

    CrossRef

  47. 47
    Hymie Anisman, Michael O. Poulter, Reno Gandhi, Zul Merali, Shawn Hayley, Interferon-α effects are exaggerated when administered on a psychosocial stressor backdrop: Cytokine, corticosterone and brain monoamine variations, Journal of Neuroimmunology, 2007, 186, 1-2, 45

    CrossRef

  48. 48
    Arne Schäfer, Hans-Ulrich Wittchen, Jochen Seufert, Michael R. Kraus, Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C – a critical review, International Journal of Methods in Psychiatric Research, 2007, 16, 4
  49. 49
    C. L. RAISON, B. J. WOOLWINE, M. F. DEMETRASHVILI, A. S. BORISOV, R. WEINREIB, J. P. STAAB, J. M. ZAJECKA, C. J. BRUNO, M. A. HENDERSON, J. F. REINUS, D. L. EVANS, G. M. ASNIS, A. H. MILLER, Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C, Alimentary Pharmacology & Therapeutics, 2007, 25, 10
  50. 50
    Ondria C. Gleason, John C. Fucci, William R. Yates, Michelle A. Philipsen, Preventing Relapse of Major Depression During Interferon-α Therapy for Hepatitis C—A Pilot Study, Digestive Diseases and Sciences, 2007, 52, 10, 2557

    CrossRef

  51. 51
    Michael R. Kraus, Oliver Al-Taie, Arne Schäfer, Matthias Pfersdorff, Klaus–Peter Lesch, Michael Scheurlen, Serotonin-1A Receptor Gene HTR1A Variation Predicts Interferon-Induced Depression in Chronic Hepatitis C, Gastroenterology, 2007, 132, 4, 1279

    CrossRef

  52. 52
    Arne Schäfer, Michael Scheurlen, Benedikt Weissbrich, Katrin Schöttker, Michael R. Kraus, Sustained Virological Response in the Antiviral Therapy of Chronic Hepatitis C: Is There a Predictive Value of Interferon-Induced Depression?, Chemotherapy, 2007, 53, 4, 292

    CrossRef

  53. 53
    L. CASTERA, A. CONSTANT, C. HENRY, P. CHAMPBENOIT, P.-H. BERNARD, V. DE LEDINGHEN, J. DEMOTES-MAINARD, P. COUZIGOU, Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C, Alimentary Pharmacology & Therapeutics, 2006, 24, 8
  54. 54
    Stanislas Pol, Vincent O Mallet, Improving anti-hepatitis C virus therapy, Expert Opinion on Biological Therapy, 2006, 6, 9, 923

    CrossRef

  55. 55
    Gregory M. Asnis, Richard De La Garza, Interferon-Induced Depression in Chronic Hepatitis C: A Review of Its Prevalence, Risk Factors, Biology, and Treatment Approaches, Journal of Clinical Gastroenterology, 2006, 40, 4, 322

    CrossRef

  56. 56
    Jason E. Farley, David J. Dial, Marguerite Littleton-Kearney, Management of Hematologic and Neuropsychiatric Side Effects in Treatment of Chronic HCV Infection, The Journal for Nurse Practitioners, 2006, 2, 1, 38

    CrossRef

  57. 57
    Rudolf E. Stauber, Vanessa Stadlbauer, Novel approaches for therapy of chronic hepatitis C, Journal of Clinical Virology, 2006, 36, 2, 87

    CrossRef

  58. 58
    S. McNally, M. Temple-Smith, W. Sievert, M. K. Pitts, Now, later or never? Challenges associated with hepatitis C treatment, Australian and New Zealand Journal of Public Health, 2006, 30, 5
  59. 59
    Sergey Akimov, Oluwatoyin M Adeyemi, Peginterferon-α2ain the treatment of chronic hepatitis C, Future Virology, 2006, 1, 6, 689

    CrossRef

  60. 60
    Ricard Solà, Josep Antón Galeras, Silvia Montoliu, Cristina Tural, Lluis Force, Sandra Torra, Santiago Montull, Eduardo Rodríguez De Castro, Susanna Coll, Daniel Fuster, Pilar Barrufet, Guillem Sirera, Maria Dolors Giménez, Bonaventura Clotet, Ramón Planas, Poor Response to Hepatitis C Virus (HCV) Therapy in HIV- and HCV-Coinfected Patients Is Not Due to Lower Adherence to Treatment, AIDS Research and Human Retroviruses, 2006, 22, 5, 393

    CrossRef

  61. 61
    Muhamad Aly Rifai, David Indest, Jennifer Loftis, Peter Hauser, Psychiatric management of the hepatitis C patient, Current Treatment Options in Gastroenterology, 2006, 9, 6, 508

    CrossRef

  62. 62
    Maria Buti, John Wong, Miguel Angel Casado, Rafael Esteban, Quality of life and cost-effectiveness of anti-HCV therapy in HIV-infected patients, Journal of Hepatology, 2006, 44, S60

    CrossRef

  63. 63
    Thierry Thevenot, Vincent Di Martino, Françoise Lunel-Fabiani, Claire Vanlemmens, Marie-Claude Becker, Jean-Pierre Bronowicki, Solange Bresson-Hadni, Jean-Philippe Miguet, Traitements complémentaires de l’hépatite chronique virale C, Gastroentérologie Clinique et Biologique, 2006, 30, 2, 197

    CrossRef

  64. 64
    Stefan Mauss, Treatment of viral hepatitis in HIV–coinfected patients–adverse events and their management, Journal of Hepatology, 2006, 44, S114

    CrossRef

  65. 65
    Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions, 2006,

    CrossRef

  66. 66
    Guy A. Farber, Tomer Levin, Craig A. White, A cognitive therapy conceptualization of panic disorder exacerbated by interferon treatment, General Hospital Psychiatry, 2005, 27, 5, 329

    CrossRef

  67. 67
    Jennifer M. Loftis, Peter Hauser, Comments on the paper ‘The effect of a herbal medicine (Mao-to) for the prevention of interferon-induced psychiatric complications in chronic hepatitis C: a pilot study’, Human Psychopharmacology: Clinical and Experimental, 2005, 20, 3
  68. 68
    M. Germana Orrù, Antonella Baita, Rossella Sitzia, Alessandra Costa, Elisabetta Muntoni, Sabine Landau, Luchino Chessa, M. Giulia Farci, Bernardo Carpiniello, Carmine M. Pariante, Interferon-alpha-induced psychiatric side effects in patients with chronic viral hepatitis: a prospective, observational, controlled study, Epidemiologia e Psichiatria Sociale, 2005, 14, 03, 145

    CrossRef

  69. 69
    Gregory M. Asnis, Richard De La Garza, Interferon-induced depression: Strategies in treatment, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2005, 29, 5, 808

    CrossRef

  70. 70
    Laurent Castéra, Aymery Constant, Chantal Henry, Patrice Couzigou, Manifestations psychiatriques au cours du traitement de l’hépatite chronique C, Gastroentérologie Clinique et Biologique, 2005, 29, 2, 123

    CrossRef

  71. 71
    Piero Amodio, Enrico N. De Toni, Luisa Cavalletto, Daniela Mapelli, Elisabetta Bernardinello, Franco Del Piccolo, Cristina Bergamelli, Raffaella Costanzo, Federica Bergamaschi, Stefano Zanone Poma, Liliana Chemello, Angelo Gatta, Giulia Perini, Mood, cognition and EEG changes during interferon α (alpha-IFN) treatment for chronic hepatitis C, Journal of Affective Disorders, 2005, 84, 1, 93

    CrossRef

  72. 72
    J Finsterer, O Sommer, M Stiskal, Multifocal leukoencephalopathy and polyneuropathy after 18 years on interferon a, Leukemia & Lymphoma, 2005, 46, 2, 277

    CrossRef

  73. 73
    Charles L Raison, Marina Demetrashvili, Lucile Capuron, Andrew H Miller, Neuropsychiatric Adverse Effects of Interferon-??, CNS Drugs, 2005, 19, 2, 105

    CrossRef

  74. 74
    Bonnie Kolor, Patient Education and Treatment Strategies Implemented at a Pharmacist-Managed Hepatitis C Virus Clinic, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2005, 25, 9
  75. 75
    Ivanka Zic, Peginterferon Alpha/Ribavirin Combination Therapy for the Treatment of Hepatitis C Infection, Gastroenterology Nursing, 2005, 28, 4, 317

    CrossRef

  76. 76
    Martin Schaefer, Markus Schwaiger, Andrea S. Garkisch, Maurice Pich, Axel Hinzpeter, Ralf Uebelhack, Andreas Heinz, Florian van Boemmel, Thomas Berg, Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C, Journal of Hepatology, 2005, 42, 6, 793

    CrossRef

  77. 77
    M. R. Kraus, A. Schäfer, O. Al-Taie, M. Scheurlen, Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression, Journal of Viral Hepatitis, 2005, 12, 1
  78. 78
    S. Hayley, M.O. Poulter, Z. Merali, H. Anisman, The pathogenesis of clinical depression: Stressor- and cytokine-induced alterations of neuroplasticity, Neuroscience, 2005, 135, 3, 659

    CrossRef

  79. 79
    Brian L. Pearlman, Hepatitis C Infection: A Clinical Review, Southern Medical Journal, 2004, 97, 4, 365

    CrossRef

  80. 80
    Brian L. Pearlman, Hepatitis C treatment update, The American Journal of Medicine, 2004, 117, 5, 344

    CrossRef

  81. 81
    Peter Hauser, Neuropsychiatric side effects of HCV therapy and their treatment: focus on IFNα-induced depression, Gastroenterology Clinics of North America, 2004, 33, 1, 37

    CrossRef

  82. 82
    S.James Matthews, Christopher McCoy, Peginterferon alfa-2a: A review of approved and investigational uses, Clinical Therapeutics, 2004, 26, 7, 991

    CrossRef

  83. 83
    Montserrat Laguno, Javier Murillas, Jos?? Luis Blanco, Esteban Mart??nez, Rosa Miquel, Jos?? M S??nchez-Tapias, Xavier Bargallo, Angeles Garc??a-Criado, Elisa de Lazzari, Mar??a Larrousse, Agathe Le??n, Montserrat Lonc??, Ana Milinkovic, Josep M Gatell, Josep Mallolas, Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients, AIDS, 2004, 18, 13, 27

    CrossRef

  84. 84
    Zorica Nesic, Dragan Delic, Milica Prostran, Radan Stojanovic, Sonja Vuckovic, Zoran Todorovic, Psychiatric adverse effects induced by recombinant interferon alfa in patients with chronic hepatitis C, Medicinski pregled, 2004, 57, 5-6, 219

    CrossRef

  85. 85
    Jennifer M. Loftis, Peter Hauser, The phenomenology and treatment of interferon-induced depression, Journal of Affective Disorders, 2004, 82, 2, 175

    CrossRef

  86. 86
    Robert G. Gish, Treating hepatitis C: the state of the art, Gastroenterology Clinics of North America, 2004, 33, 1, 1

    CrossRef

  87. 87
    Thierry Vial, Jacques Descotes, Corinna Ludwig, Matthias Behrend, 2004,

    CrossRef

  88. 88
    Colleen P. Corcoran, Neuropsychiatric Changes in HIV/Hepatitis C Coinfected Patients Undergoing Interferon Therapy, Journal of the Association of Nurses in AIDS care, 2003, 14, 5, 80S

    CrossRef

  89. 89
    Mark W. Russo, Michael W. Fried, Side effects of therapy for chronic hepatitis C, Gastroenterology, 2003, 124, 6, 1711

    CrossRef

  90. 90
    Deborah Antai-Otong, Treatment Considerations for the Client With Interferon-Alpha-Induced Depression, Perspectives in Psychiatric Care, 2003, 39, 4
  91. 91
    Michael W. Fried, Side effects of therapy of hepatitis C and their management, Hepatology, 2002, 36, S1
  92. 92
    Doris B. Strader, Understudied populations with hepatitis C, Hepatology, 2002, 36, S1
  93. 93
    Thomas J. Connor, Andrew Harkin, Inflammation in the Pathogenesis of Depression,
  94. 94
    Elizabeth G. Pinsky, Annah N. Abrams, Psychopharmacology in Pediatric Oncology,